الصفحة الرئيسية>>Signaling Pathways>> Angiogenesis>> BTK>>Pirtobrutinib

Pirtobrutinib (Synonyms: LOXO-305, LY3527727)

رقم الكتالوجGC62515

Pirtobrutinib (LOXO-305) ، مثبط BTK انتقائي للغاية وغير تساهمي من الجيل التالي ، يمنع طفرات استبدال BTK C481 المتنوعةيتسبب Pirtobrutinib في تراجع أورام سرطان الغدد الليمفاوية المعتمدة على BTK في نماذج طعم أجنبي للفأريعتبر Pirtobrutinib أيضًا أكثر من 300 ضعفًا انتقائيًا لـ BTK مقابل 370 كينازات أخرى تم اختبارها ولا يُظهر أي تثبيط كبير للأهداف غير الكينازية عند 1 ميكرومتر

Products are for research use only. Not for human use. We do not sell to patients.

Pirtobrutinib التركيب الكيميائي

Cas No.: 2101700-15-4

الحجم السعر المخزون الكميّة
10mM (in 1mL DMSO)
67٫00
متوفر
1mg
29٫00
متوفر
5mg
63٫00
متوفر
10mg
112٫00
متوفر
25mg
259٫00
متوفر
50mg
392٫00
متوفر

Tel:(909) 407-4943 Email: sales@glpbio.com


مراجعات العميل

بناء على آراء العملاء.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description of Pirtobrutinib

Pirtobrutinib (LOXO-305), a highly selective and non-covalent next generation BTK inhibitor, inhibits diverse BTK C481 substitution mutations. Pirtobrutinib causes regression of BTK-dependent lymphoma tumors in mouse xenograft models. Pirtobrutinib is also more than 300-fold selective for BTK versus 370 other kinases tested and shows no significant inhibition of non-kinase off-targets at 1 μM[1].

Pirtobrutinib potently inhibits both wild-type BTK and BTK C481S-mediated kinase activity with nanomolar potency. Pirtobrutinib inhibits WT BTK (Y223) autophosphorylation with an IC50 of 3.68 nM. Pirtobrutinib inhibits BTK C481S Y223, C481T Y223, and C481R Y223 autophosphorylation with IC50s of 8.45, 7.23, and 11.73 nM, respectively[1].

[1]. Gomez E B , et al. Loxo-305, a Highly Selective and Non-Covalent Next Generation BTK Inhibitor, Inhibits Diverse BTK C481 Substitution Mutations[J]. Blood, 2019, 134(Supplement_1):4644-4644.

Chemical Properties of Pirtobrutinib

Cas No. 2101700-15-4 SDF
المرادفات LOXO-305, LY3527727
Formula C22H21F4N5O3 M.Wt 479.43
الذوبان DMSO : 50 mg/mL (104.29 mM; Need ultrasonic) Storage 4°C, stored under nitrogen
General tips Please select the appropriate solvent to prepare the stock solution according to the solubility of the product in different solvents; once the solution is prepared, please store it in separate packages to avoid product failure caused by repeated freezing and thawing.Storage method and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored at -20°C, please use it within 1 month.
To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time.
Shipping Condition Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request.

Complete Stock Solution Preparation Table of Pirtobrutinib

Prepare stock solution
1 mg 5 mg 10 mg
1 mM 2.0858 mL 10.4291 mL 20.8581 mL
5 mM 0.4172 mL 2.0858 mL 4.1716 mL
10 mM 0.2086 mL 1.0429 mL 2.0858 mL
  • حاسبة المولارية

  • حاسبة التخفيف

  • Molecular Weight Calculator

كتلة
=
تركيز
x
مقدار
x
ميغاواط *
 
 
 
** عند إعداد حلول المخزون، دائمًا استخدم الوزن الجزيئي الخاص بالدفعة للمنتج على ملصق القارورة MSDS / CoA (متوفر عبر الإنترنت).

احسب

In vivo Formulation Calculator (Clear solution) of Pirtobrutinib

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

Product Documents

Quality Control & SDS

View current batch:

مراجعات

Review for Pirtobrutinib

Average Rating: 5 ★★★★★ (Based on Reviews and 32 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Pirtobrutinib

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.